Posts tagged renal disease
Stifel ups Reata price target to $50

Stifel raised its price target for “buy-rated” Reata Pharmaceuticals (NASDAQ:RETA) to $50 from $38 after the company reported statistically significant improvements in kidney function from the Phase 2 portion of its Cardinal study evaluating BARD in Alport chronic kidney disease (CKD). The stock closed at $37.66 on July 24.

Read More
Fresenius extends Endexo accord with Interface Biologics

Fresenius Medical Care (FSE:FME; NYSE:FMS) has extended its exclusive licensing agreement with closely-held Interface Biologics for use of the Endexo technology in chronic dialysis systems to cover the acute dialysis market, including continuous renal replacement therapy.

Interface BiologicsInterface’s Endexo is a self-locating fluoro-oligomeric additive that results in a passive surface that reduces platelet adhesion and activation, protein adsorption and thrombus formation in medical devices, potentially reducing the use of drugs such as heparin.

Read More